Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…Abstract Number: 2446 • 2018 ACR/ARHP Annual Meeting
The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate
Background/Purpose: Lymphoproliferative disorders (LPDs) are a serious complication in patients with rheumatoid arthritis (RA). Methotrexate (MTX) is known to be able to cause a development…Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…Abstract Number: 959 • 2018 ACR/ARHP Annual Meeting
The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
Background/Purpose: MTX has become the cornerstone in treatment of many rheumatologic disorders including rheumatoid arthritis and psoriasis. Although MTX can have a profound impact on…Abstract Number: 2819 • 2018 ACR/ARHP Annual Meeting
Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of premature cardiovascular events and mortality. Prospective general population studies have shown moderate alcohol consumption…Abstract Number: 1419 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
Background/Purpose: Linear Scleroderma (LS) is the most common subtype of localized Scleroderma in children and the one most frequently associated with tissue damage and functional…Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…Abstract Number: 1494 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches
Background/Purpose: As a step towards personalized medicine, we seek to identify patients with new-onset RA who are likely to remain well on MTX monotherapy. Patients…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 16
- Next Page »